Know Cancer

forgot password

An Open-Label Phase I Study of Weekly ABI-007 and Vinorelbine With or Without G-CSF in Patients With Stage IV (Metastatic) Breast Cancer

Phase 1
18 Years
Not Enrolling
Stage IV (Metastatic) Breast Cancer

Thank you

Trial Information

An Open-Label Phase I Study of Weekly ABI-007 and Vinorelbine With or Without G-CSF in Patients With Stage IV (Metastatic) Breast Cancer

Inclusion Criteria:

- Patient has microscopically confirmed invasive breast carcinoma with clinical
and/or radiographic evidence of stage 4 disease. If diagnosis is based on pleural
effusion, positive cytology must be confirmed.

- Patient has had no prior chemotherapy for Stage IV disease (hormone therapy is
permitted). Prior adjuvant paclitaxel by 3-hour infusion is permitted, if there is no
residual neuropathy. Prior adjuvant docetaxel on an every 3 week schedule is

- Disease must be measurable (unidimensional by RECIST criteria)or evaluable (e.g.,
malignant effusion, marrow involvement). Elevated tumor markers alone are

- Age >18.

- SWOG (ECOG) performance status must be < or =2 at screen and on treatment day one.

- Life expectancy must be estimated at >16 weeks.

- Prior irradiation is permitted, provided:

- Does not exceed 25% of the estimated bone marrow volume (see Appendix I).

- Measurable/evaluable disease exists outside the radiation field, or progressive
disease is documented within the radiation field.

- Informed consent must be obtained prior to registration.

- Patients must be > 2 weeks from prior surgery; > 3 weeks from radiation therapy to
the pelvis, spine or long bones; > 3 weeks from prior chemotherapy (> 6 weeks for
mitomycin C or nitrosureas), or > 2 weeks from prior hormonal therapy.

- All patients must have placement of appropriate central venous access device.

- Tumor HER2/neu expression must be determined prior to study enrollment. Assessment
may be by fluorescence in situ hybridization (FISH) assay or by immunohistochemistry
(ICC). If determination is intermediate by ICC, FISH must be performed. For
enrollment purposes, this phase I study will not discriminate based on HER2 status.
However, documentation of patients' HER2 status will be maintained and Herceptin will
be prescribed for all HER2 positive patients.

Exclusion Criteria:

- Granulocytes < 1,500/mm3.

- Platelets < 100,000/mm3.

- Hemoglobin < 9 gm/dl.

- Creatinine > 2.0 mg/dl.

- Total bilirubin > 2 mg/dl.

- Visceral crisis characterized by rapidly progressive hepatic or lymphangitic lung

- Medically unstable as judged by the patient's physician.

- Pregnancy or lactation; failure to employ adequate contraception.

- Uncontrolled CNS disease.

- Pre-existing Grade ≥ 2 peripheral neuropathy except for abnormalities due to cancer.

- Psychological, familial, sociological or geographical conditions which do not permit
weekly medical follow-up and compliance with the study protocol.

- Prior therapy with vinorelbine or prior therapy with a taxane that resulted in

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

optimal tolerated dose of ABI-007 and vinorelbine, given concurrently on a weekly basis, in the absence of planned growth factor support


United States: Food and Drug Administration

Study ID:




Start Date:

August 2005

Completion Date:

August 2007

Related Keywords:

  • Stage IV (Metastatic) Breast Cancer
  • Breast Neoplasms



Seattle Cancer Care Alliance Seattle, Washington  98109
City of Hope Comprehensive Cancer Care Center Duarte, California  91010